GlassScriptPhysician profile
Joseph Gutierrez
NPI 1538143300
$8,075.84
in general payments reported to CMS, 2019-2025
33 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $1,171 · 2021: $1,319 · 2022: $916 · 2023: $542 · 2024: $1,148 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.66 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,700.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $958.40 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $841.67 | 2021-2025 | Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.20 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $631.62 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $538.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $392.23 | 2022-2025 | |
| Madrigal Pharmaceuticals | $270.80 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $196.31 | 2019-2020 | |
| Nevro Corp. | $149.31 | 2019 | |
| Exact Sciences Corporation | $146.84 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $145.73 | 2019-2025 | Watchman Flx |
| Stemline Therapeutics INC. | $142.23 | 2025 | Orserdu |
| Medtronic, INC. | $118.29 | 2024 | Interstim |
| Acadia Pharmaceuticals INC | $117.05 | 2024 | Daybue |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $115.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $107.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $107.17 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $106.88 | 2019 | |
| Asahi Intecc USA, INC. | $92.08 | 2025 | Asahi Interventional Radiology Wires |
| Davol INC. | $74.45 | 2021 | |
| Glaxosmithkline, LLC. | $65.86 | 2023-2024 | Shingrix |
| Merck Sharp & Dohme LLC | $49.94 | 2019-2020 | |
| Astellas Pharma US INC | $42.06 | 2024 | Veozah |
| Penumbra, INC. | $33.76 | 2025 | Indigo System |
| Hologic Sales and Service, LLC | $23.93 | 2023 | Aptima |
| Eisai INC. | $20.40 | 2020 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Intuitive Surgical, INC. | $16.16 | 2021 | |
| Gilead Sciences, INC. | $16.10 | 2025 | |
| Endogastric Solutions, INC | $14.79 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.